Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guntram Schernthaner

Showing results (1-10 of 133) with videos related to

Pageof 14
Sort By:
Wiener Klinische Wochenschrift|January 28, 2004
[Progress in the prevention of type 2 diabetes]Guntram Schernthaner
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 23, 2010
Kidney disease in diabetology: lessons from 2009Guntram Schernthaner
The Lancet. Diabetes & Endocrinology|April 2, 2021
Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?Guntram Schernthaner
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 29, 2011
Kidney disease in diabetology: lessons from 2010Guntram Schernthaner
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 16, 2009
Kidney disease in diabetology: lessons from 2008Guntram Schernthaner
Metabolism: Clinical and Experimental|August 27, 2003
Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effectsGuntram Schernthaner
Diabetes & Metabolism Journal|August 6, 2021
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)Guntram Schernthaner
Acta Medica Austriaca|March 8, 2005
[Hypertension]Guntram Schernthaner
Atherosclerosis. Supplements|August 2, 2005
Is dyslipidaemia important if we control glycaemia?Guntram Schernthaner
Wiener Medizinische Wochenschrift (1946)|March 16, 2010
Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGARGuntram Schernthaner
Pageof 14

Showing results (1-10 of 133) with videos related to

Sort By:
Pageof 14
Wiener Klinische Wochenschrift|January 28, 2004
[Progress in the prevention of type 2 diabetes]Guntram Schernthaner
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 23, 2010
Kidney disease in diabetology: lessons from 2009Guntram Schernthaner
The Lancet. Diabetes & Endocrinology|April 2, 2021
Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?Guntram Schernthaner
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 29, 2011
Kidney disease in diabetology: lessons from 2010Guntram Schernthaner
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 16, 2009
Kidney disease in diabetology: lessons from 2008Guntram Schernthaner
Metabolism: Clinical and Experimental|August 27, 2003
Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effectsGuntram Schernthaner
Diabetes & Metabolism Journal|August 6, 2021
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)Guntram Schernthaner
Acta Medica Austriaca|March 8, 2005
[Hypertension]Guntram Schernthaner
Atherosclerosis. Supplements|August 2, 2005
Is dyslipidaemia important if we control glycaemia?Guntram Schernthaner
Wiener Medizinische Wochenschrift (1946)|March 16, 2010
Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGARGuntram Schernthaner
Pageof 14